Market News & Trends
International Stem Cell Corporation Developed 3D Liver Structures
International Stem Cell Corporation recently announced that ISCO’s Research and Development team has developed novel methods that efficiently generate human 3D liver-like tissue. According to…
Innovest Global Signs Worldwide Agreement With Cedars-Sinai Medical Center to Commercialize Vaccine
StemVax Therapeutics, an Innovest Global Inc. holding, has been awarded an exclusive worldwide license agreement from Cedars-Sinai Medical Center in Los Angeles, CA, for all…
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement to Advance AAV Gene Therapy Technology
Fortress Biotech recently announced that its subsidiary, Aevitas Therapeutics, Inc. has entered into a sponsored research agreement (SRA) with the laboratory of Wenchao Song, PhD,…
Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Therapeutics Solutions International, Inc. recently announced successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The…
Nevakar & Endo Enter Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products
Nevakar Inc. recently announced it entered into an exclusive licensing agreement with Endo International plc’s subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the US and Canada.
Credence MedSystems Closes $12.8-Million Financing to Support Ongoing Development & Scaling of Innovative Delivery Products
Credence MedSystems, Inc., an innovator in injectable drug delivery devices, recently announced the closing of a Series B financing resulting in gross proceeds to the company of $12.8 million.
Avalon GloboCare Forms Strategic Partnership With Weill Cornell Medical College to Co-develop Technologies & Bio-production of CAR-T Therapy
This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards.
Vasomune Therapeutics & AnGes, Inc. Enter Multi-Million Dollar Global Co-Development Agreement
Vasomune Therapeutics and AnGes, Inc. recently announced the signing of an innovative global co-development agreement for the development and commercialization of therapeutics treating diseases associated…
Cantabio Pharmaceuticals to Present Positive In Vivo Efficacy Results
Cantabio Pharmaceuticals Inc. recently announced that Dr. Gergely Toth, Cantabio's CEO, will present results from the company's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic…
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
Moleculin Biotech, Inc. recently announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults.…
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA
ARCA Biopharma, Inc. recently announced it has received guidance from the US FDA following an End-of-Phase 2 meeting regarding the Phase 3 program for ARCA’s…
BioPharmX Receives IRB Approval to Initiate Phase 2 Trial
BioPharmX Corporation recently announced it has received Institutional Review Board approval for its Phase 2 study of BPX-04 for the treatment of papulopustular rosacea. The…
Baxter Announces Health Canada Approval of Spectrum IQ Infusion System
Baxter Canada recently announced Health Canada approval for the Spectrum IQ Infusion System with Dose IQ Safety Software. The Spectrum IQ system features new bi-directional electronic medical records (EMR) integration to help…
Croda Invests in SiSaf’s Novel Bio-Courier Technology
Croda International Plc and SiSaf Ltd recently announced an exciting new strategic partnership. Croda, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has agreed a commercial arrangement with SiSaf, a pioneering UK-based biopharmaceutical company.
Microfluidic Modulation Spectroscopy (MMS) For Protein Therapeutic Drug Analysis
Automated, high sensitivity spectroscopic analyses for the development, formulation and manufacture of biotherapeutics are now available thanks to RedShiftBio’s new AQS3pro protein characterization platform. The system is based on Microfluidic Modulation Spectroscopy (MMS) technology. Read this application note to learn about how MMS characterizes higher order protein structures, the mechanisms of protein stability, aggregation, protein similarity and quantitation.
ABITEC Corporation & DKSH Announce Specialty Lipid Distribution Agreement
ABITEC Corporation, a global manufacturer of specialty lipids, has executed a multi-year agreement with distribution partner DKSH to market and sell its ingredients into select…
Translate Bio Announces Closing of Collaboration & Licensing Agreement with Sanofi Pasteur
Translate Bio recently announced the closing of a previously announced research collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to…
WuXi Biologics & Immune Pharmaceuticals Announce Late-Phase Development & Manufacturing Partnership
WuXi Biologics and Immune Pharmaceuticals recently announced a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed…
FDA Grants Fast-Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor
Aclaris Therapeutics, Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3…
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen in combination with FluMist…
